MX359201B - Polipeptidos que se unen al complemento humano 5 (c5). - Google Patents

Polipeptidos que se unen al complemento humano 5 (c5).

Info

Publication number
MX359201B
MX359201B MX2014009879A MX2014009879A MX359201B MX 359201 B MX359201 B MX 359201B MX 2014009879 A MX2014009879 A MX 2014009879A MX 2014009879 A MX2014009879 A MX 2014009879A MX 359201 B MX359201 B MX 359201B
Authority
MX
Mexico
Prior art keywords
polypeptides
join
human complement
amino acid
acid sequence
Prior art date
Application number
MX2014009879A
Other languages
English (en)
Spanish (es)
Other versions
MX2014009879A (es
Inventor
Berghard Charlotta
Berglund Magnus
Strömberg Patrik
Lindborg Malin
Gunneriusson Elin
Feldwisch Joachim
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Publication of MX2014009879A publication Critical patent/MX2014009879A/es
Publication of MX359201B publication Critical patent/MX359201B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
MX2014009879A 2012-02-20 2013-02-19 Polipeptidos que se unen al complemento humano 5 (c5). MX359201B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1250145 2012-02-20
PCT/SE2013/050139 WO2013126006A1 (en) 2012-02-20 2013-02-19 Polypeptides binding to human complement c5

Publications (2)

Publication Number Publication Date
MX2014009879A MX2014009879A (es) 2014-11-10
MX359201B true MX359201B (es) 2018-09-19

Family

ID=49006055

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009879A MX359201B (es) 2012-02-20 2013-02-19 Polipeptidos que se unen al complemento humano 5 (c5).

Country Status (31)

Country Link
US (5) US9808502B2 (enExample)
EP (3) EP4616914A3 (enExample)
JP (2) JP6276202B2 (enExample)
KR (2) KR102336895B1 (enExample)
CN (1) CN104114574B (enExample)
AU (3) AU2013222836B2 (enExample)
BR (1) BR112014020427B1 (enExample)
CA (1) CA2863862C (enExample)
CY (1) CY1121455T1 (enExample)
DK (1) DK2817329T3 (enExample)
ES (1) ES2715638T3 (enExample)
HR (1) HRP20190522T1 (enExample)
HU (1) HUE041996T2 (enExample)
IL (2) IL234114B (enExample)
LT (1) LT2817329T (enExample)
ME (1) ME03640B (enExample)
MX (1) MX359201B (enExample)
MY (1) MY167232A (enExample)
NZ (1) NZ628625A (enExample)
PH (1) PH12014501604B1 (enExample)
PL (1) PL2817329T3 (enExample)
PT (1) PT2817329T (enExample)
RS (1) RS58503B1 (enExample)
RU (1) RU2654668C2 (enExample)
SG (1) SG11201404942UA (enExample)
SI (1) SI2817329T1 (enExample)
SM (1) SMT201900189T1 (enExample)
TR (1) TR201903840T4 (enExample)
UA (1) UA117096C2 (enExample)
WO (1) WO2013126006A1 (enExample)
ZA (1) ZA201406773B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4616914A3 (en) 2012-02-20 2025-11-19 IPC Research, LLC Polypeptides binding to human complement c5
KR102151289B1 (ko) 2012-10-25 2020-09-02 애피바디 에이비 Abd 결합 폴리펩티드
ES2674983T3 (es) 2012-10-25 2018-07-05 Affibody Ab Método para la separación de proteínas que contienen un dominio que se une a albúmina
KR102446636B1 (ko) * 2013-08-28 2022-09-23 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 안정한 폴리펩티드
KR20160068744A (ko) 2013-08-28 2016-06-15 애피바디 에이비 돌연변이된 스캐폴드를 갖는 결합 폴리펩티드
PL3628680T3 (pl) 2014-06-12 2022-01-10 Ra Pharmaceuticals, Inc. Modulowanie aktywności dopełniacza
JP6678661B2 (ja) 2014-06-13 2020-04-08 アフィボディ アクティエボラーグ 新規ポリペプチド
EP3154563B1 (en) * 2014-06-13 2019-08-14 Affibody AB New polypeptide
DE102014225439A1 (de) * 2014-12-10 2016-06-16 Zf Friedrichshafen Ag Stufenplanet
KR20240110106A (ko) * 2015-01-12 2024-07-12 애피바디 에이비 Il-17a-결합 폴리펩티드
EP3988110A1 (en) 2015-01-28 2022-04-27 RA Pharmaceuticals, Inc. Modulators of complement activity
WO2017105939A1 (en) 2015-12-16 2017-06-22 Ra Pharmaceuticals, Inc. Modulators of complement activity
EP3551210A1 (en) 2016-12-07 2019-10-16 RA Pharmaceuticals, Inc. Modulators of complement activity
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
IL271920B2 (en) * 2017-07-11 2024-03-01 Alexion Pharma Inc Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
BR112021019803A2 (pt) 2019-04-03 2021-12-07 Clean Earth Tech Pty Ltd Materiais e processos para recuperação de metais preciosos
US20220389066A1 (en) * 2019-11-05 2022-12-08 Affibody Ab Polypeptides
US20230357442A1 (en) * 2020-10-05 2023-11-09 Alexion Pharmaceuticals, Inc. Methods of treating dermatomyositis
WO2024227886A1 (en) 2023-05-02 2024-11-07 Mebrahtu Aman Bispecific binding molecule

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
JPH09510088A (ja) 1994-03-03 1997-10-14 アレクション・ファーマシューティカル・インク 最終補体インヒビター融合遺伝子およびタンパク質
ES2236706T3 (es) 1994-03-23 2005-07-16 Alexion Pharmaceuticals, Inc. Procedimiento para reducir las disfunciones de los sistemas inmunitario y hemostatico durante la circulacion extracorporal.
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JP3971797B2 (ja) 1994-09-23 2007-09-05 アレクション・ファーマシューティカルズ・インク 炎症性関節疾患の治療方法
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
EP2113516B1 (en) 2000-10-10 2014-05-21 Genentech, Inc. Antibodies against C5 inhibiting type II endothelial cell activation
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
ATE360441T1 (de) * 2001-08-17 2007-05-15 Tanox Inc Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
CN1745098A (zh) 2002-12-02 2006-03-08 瑞希斯顿蒂亚药品股份公司 用含自身c5氨基酸区段和非自身氨基酸区段的多肽治疗炎性疾病的方法和材料
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
MXPA05012880A (es) 2003-06-02 2006-02-22 Evolutec Ltd Inhibidores de complemento.
EP1667702A2 (en) 2003-09-10 2006-06-14 Baxter International Inc., Baxter Healthcare Corp. Peptides that inhibit complement activation
SE0400274D0 (sv) 2004-02-09 2004-02-09 Affibody Ab New polypeptide
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US7838244B2 (en) 2004-03-24 2010-11-23 Auckland Uniservices Limited SET1 proteins and uses thereof
DE05733048T1 (de) 2004-04-06 2007-05-10 Affibody Ab Serumalbuminbindende peptidkonjugate zur arzneimittelherstellung
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
NZ567483A (en) * 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
GB0524788D0 (en) 2005-12-05 2006-01-11 Affibody Ab Polypeptides
DK1991275T3 (en) 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
EP3124029A1 (en) 2006-03-15 2017-02-01 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
WO2008010902A2 (en) 2006-07-06 2008-01-24 The Trustees Of The University Of Pennsylvania Regulation of tlr signaling by complement
CA2662480C (en) 2006-09-05 2016-11-08 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
KR20090060334A (ko) * 2006-09-08 2009-06-11 제넨테크, 인크. Ｗｎｔ 길항제 및 ｗｎｔ-매개 장애의 진단 및 치료에서의 이의 용도
BRPI0809105A2 (pt) * 2007-03-22 2019-09-10 Novartis Ag antígenos c5 e uso destes
WO2008154018A2 (en) 2007-06-11 2008-12-18 The Trustees Of The University Of Pennsylvania Properdin modulation of alternative pathway and uses thereof
CA2694139C (en) 2007-07-31 2018-06-05 Affibody Ab Albumin binding polypeptide compositions
US8852869B2 (en) 2007-09-05 2014-10-07 Immunobond Aps Method of determining functional deficiencies in the complement system
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
US9187535B2 (en) * 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
ATE527353T1 (de) 2007-12-19 2011-10-15 Affibody Ab Pdgf-bindendes polypeptid aus protein a
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
HUE026179T2 (en) * 2008-08-05 2016-05-30 Novartis Ag Preparations and methods for antibodies against complement C5 protein
BRPI0921237A2 (pt) 2008-11-10 2015-09-22 Alexion Pharma Inc métodos e composições para o tratamento de distúrbios associados ao complemento
EP2327725A1 (en) * 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
MX2012010116A (es) 2010-03-01 2013-02-26 Alexion Pharma Inc Metodos y composiciones para el tratamiento de la enfermedad de degos.
US20110243942A1 (en) * 2010-04-02 2011-10-06 Athena Discovery, Inc. Relaxin-fusion proteins with extended in vivo half-lives
BR112012027900A2 (pt) 2010-04-30 2020-05-12 Alexion Pharmaceuticals, Inc. Anticorpos anti-c5a e métodos para usar os anticorpos
CN110437320B (zh) 2010-07-09 2023-10-20 阿菲博迪公司 多肽
AU2012279288B2 (en) 2011-07-01 2017-07-20 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
EP4616914A3 (en) 2012-02-20 2025-11-19 IPC Research, LLC Polypeptides binding to human complement c5
WO2013172954A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
US9957330B2 (en) 2012-12-19 2018-05-01 Affibody Ab Polypeptides
ES2660912T3 (es) 2013-03-15 2018-03-26 Affibody Ab Nuevos polipéptidos
KR102446636B1 (ko) 2013-08-28 2022-09-23 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 안정한 폴리펩티드
KR20160068744A (ko) 2013-08-28 2016-06-15 애피바디 에이비 돌연변이된 스캐폴드를 갖는 결합 폴리펩티드
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics

Also Published As

Publication number Publication date
IL267724B (en) 2022-05-01
TR201903840T4 (tr) 2019-04-22
EP4616914A3 (en) 2025-11-19
US10206975B2 (en) 2019-02-19
EP2817329A4 (en) 2015-09-02
NZ628625A (en) 2016-03-31
IL234114B (en) 2019-07-31
AU2019250239A1 (en) 2019-11-07
US11123401B2 (en) 2021-09-21
AU2017245376A1 (en) 2017-11-02
CN104114574A (zh) 2014-10-22
US20210401930A1 (en) 2021-12-30
EP4616914A2 (en) 2025-09-17
BR112014020427B1 (pt) 2023-04-04
US20180085428A1 (en) 2018-03-29
AU2019250239B2 (en) 2021-04-08
KR20140129163A (ko) 2014-11-06
JP6719438B2 (ja) 2020-07-08
US20250332214A1 (en) 2025-10-30
AU2017245376B2 (en) 2019-07-25
PH12014501604A1 (en) 2014-10-08
EP3511339B1 (en) 2025-04-09
SG11201404942UA (en) 2014-09-26
CN104114574B (zh) 2018-08-24
WO2013126006A1 (en) 2013-08-29
MX2014009879A (es) 2014-11-10
US20190167760A1 (en) 2019-06-06
LT2817329T (lt) 2019-04-10
EP2817329B1 (en) 2019-01-02
RS58503B1 (sr) 2019-04-30
KR102149028B1 (ko) 2020-08-27
SMT201900189T1 (it) 2019-05-10
ES2715638T3 (es) 2019-06-05
AU2013222836B2 (en) 2017-07-20
US20150011474A1 (en) 2015-01-08
CY1121455T1 (el) 2020-05-29
HK1204790A1 (en) 2015-12-04
DK2817329T3 (en) 2019-04-01
MY167232A (en) 2018-08-14
SI2817329T1 (sl) 2019-04-30
KR20200105953A (ko) 2020-09-09
PL2817329T3 (pl) 2019-07-31
US9808502B2 (en) 2017-11-07
HUE041996T2 (hu) 2019-07-29
HRP20190522T1 (hr) 2019-05-03
AU2013222836A1 (en) 2014-09-18
JP2018052942A (ja) 2018-04-05
ME03640B (me) 2020-07-20
PT2817329T (pt) 2019-04-01
JP6276202B2 (ja) 2018-02-07
JP2015508652A (ja) 2015-03-23
PH12014501604B1 (en) 2018-11-07
CA2863862A1 (en) 2013-08-29
RU2654668C2 (ru) 2018-05-21
IL267724A (en) 2019-08-29
KR102336895B1 (ko) 2021-12-08
BR112014020427A8 (pt) 2018-01-23
US12083160B2 (en) 2024-09-10
CA2863862C (en) 2021-03-16
EP2817329A1 (en) 2014-12-31
UA117096C2 (uk) 2018-06-25
EP3511339A1 (en) 2019-07-17
RU2014137303A (ru) 2016-04-10
ZA201406773B (en) 2016-08-31

Similar Documents

Publication Publication Date Title
MX359201B (es) Polipeptidos que se unen al complemento humano 5 (c5).
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
EA202090919A1 (ru) Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a
MX2021014242A (es) Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.
EA201792245A1 (ru) Биоконъюгаты и их применения
MX383887B (es) Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich.
CO2019003951A2 (es) Proteínas de unión a cd123 y composiciones y métodos relacionados
PH12016500137A1 (en) Afucosylated anti-fgfr2iiib antibodies
EA201591559A1 (ru) Терапевтические пептиды
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
EA201792307A1 (ru) Способы репарации и регенерации тканей
BR112016029318A2 (pt) tratamento de mielomas
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
MX2017016322A (es) Metodos para tratar tumores de celulas epitelioides.
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
EP2552462A4 (en) CCN3 THERAPEUTIC PEPTIDES AND THEIR ANALOGS
EA201890623A1 (ru) Рациональная комбинированная терапия для лечения рака

Legal Events

Date Code Title Description
FG Grant or registration